WALDENSTROM MACROGLOBULINAEMIA
Clinical trials for WALDENSTROM MACROGLOBULINAEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINAEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINAEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: WALDENSTROM MACROGLOBULINAEMIA
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to unravel nerve damage in rare blood cancer
Knowledge-focused Recruiting nowThis study looks at why many people with Waldenström's macroglobulinemia, a rare blood cancer, develop nerve damage that can cause pain, numbness, and trouble moving. Researchers will examine 90 patients to find out how common this nerve damage is and what causes it. The goal is …
Matched conditions: WALDENSTROM MACROGLOBULINAEMIA
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:33 UTC